PSY38 HEALTH-RELATED FAMILY FUNCTIONING IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)-PATIENT INTERVIEWS SUPPORT SIX DOMAINS  by Hassette, A et al.
A212 Abstracts
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported  
Outcomes Studies
PSY35
PERSISTENCE AND COMPLIANCE OF DEFEROXAMINE VERSUS 
DEFERASIROX IN MEDICAID PATIENTS WITH SICKLE-CELL DISEASE 
(SCD)
Jordan LB1, Vekeman F2, Sengupta A3, Corral M4, Guo A5, Duh MS6
1Sickle Cell Disease Association of America, Inc., Baltimore, MD, USA, 2Analysis Group, Inc., 
Washington , DC, USA, 3Analysis Group, Inc., San Francisco, CA, USA, 4Novartis Oncology, 
East Hanover, NJ, USA, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 
6Analysis Group, Inc., Boston, MA, USA
OBJECTIVES: This study compares the frequency of hospitalizations, persistence, and 
compliance of SCD patients treated with deferoxamine (DFO) versus deferasirox 
(Exjade®), two iron chelating therapies (ICTs). METHODS: Health care claims from 
Medicaid Florida (1998–2007), Missouri (1993–2008), and New Jersey (1996–2008) 
were analyzed. Patients with continuous enrollment for ≥6 months prior to ICT initia-
tion and ≥1 SCD diagnosis were included. Patients were divided into four cohorts: 
treated with DFO (any DFO group), treated with deferasirox (any deferasirox group), 
initiated on DFO and then switched to deferasirox (deferasirox switchers), and treated 
with deferasirox only (deferasirox only group). Frequency of hospitalization for crisis 
conditions related to SCD pre- and post-ICT treatment initiation was assessed. Per-
sistence was deﬁned as time to drug discontinuation with ≥1 Rx gap. Compliance was 
estimated using the medication possession ratio (MPR) based on the drug exposure. 
RESULTS: 217, 275, 105, and 166 patients were included in the any DFO, any 
deferasirox, deferasirox switchers, and deferasirox only groups, respectively. After 
ICT initiation, the any deferasirox and deferasirox only groups experienced a signiﬁ-
cant reduction in the per patient per month frequency of hospitalizations relative to 
pre-treatment (any deferasirox: from 0.09 to 0.06, P = .0105; deferasirox only: from 
0.11 to 0.07, P = .0188). The Kaplan-Meier rates of medication persistence after one 
year of ICT were signiﬁcantly greater for all three deferasirox cohorts compared to 
the DFO cohort (any DFO: 0.21, any deferasirox: 0.29, deferasirox switchers: 0.37, 
deferasirox only: 0.24). Deferasirox treated patients were also signiﬁcantly more 
compliant than the DFO cohort (MPR, any DFO: 0.64, any deferasirox: 0.78, defera-
sirox switchers: 0.75, deferasirox only: 0.80). CONCLUSIONS: Deferasirox patients 
were more compliant and persistent to their treatment than those treated with DFO. 
Frequency of hospitalizations for SCD-related crisis conditions was signiﬁcantly 
reduced in the observation period for the any deferasirox and deferasirox only groups.
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OBJECTIVES: To address limited data in Midwest solid organ transplant recipient 
(SOTR) populations we determined the patient’s demographic and medical character-
istics associated with self-reported immunosuppressant (IST) adherence on a 4-item 
measure (ITAS). METHODS: Cross-sectional survey-data (patient: residence zip code, 
education, marital status, annual income, health-status, insurance coverage; condition: 
comorbidities; therapy: total number of medications other than IST; and ITAS) was 
received from >/= 19 year old adult SOTR of an academic transplant center located 
in mid west US. For this retrospective study, survey-data were merged with other 
patient (age, race, gender); condition (transplant-type, years since last transplant); 
IST-drug therapy-data from the center’s database. Multivariate stepwise logistic 
regression was used to identify signiﬁcant patient characteristics for the dependent 
variable of being “adherent” (ITAS score = 12) compared with being “nonadherent” 
(ITAS score <12). RESULTS: Respondents had either kidney (269 [48.5%]), liver 
(263[47.2%]), or other (23[4.5%]) transplant. Other respondent characteristics were: 
age (mean 56 years), male (55.5%), white (90.1%), married (69.9%), less than 
$55,000 annual income (57.3%), metro-resident (59%), Medicare-insurance (47.8%), 
excellent to good health status (77.5%), years since last transplant (mean 7.53 +/− SD 
5.87). The SOTRs were on different IST regimens (Tacrolimus based combination IST 
drugs, 39.2%, Tacrolimus, 22.3%, Cyclosporine, 20.7%, Cyclosporine combinations, 
9%, Other, 8.8%). More than half (320/557; 57.5%) of the SOTRs self-reported 
“adherence”. In a multivariate stepwise logistic regression model including all patient 
characteristics; age less than 65 years (p = 0.0002), living in non metro rural areas (p 
= 0.041), and greater than or equal to 6 co-morbidities (p = 0.0040) signiﬁcantly 
decreased the likelihood of adherence compared with nonadherence. In the same 
model, however, Tacrolimus based combination-IST rather than Tacrolimus alone (p 
= 0.019), signiﬁcantly increased the likelihood of adherence compared with non-
adherence. CONCLUSIONS: Our study identiﬁed patient, condition, and IST-therapy 
correlates of IST-adherence which providers may consider to deliver IST-adherence 
improving interventions.
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SCALE (VAS) AND THE EQ-5D VALUE-SETS IN PATIENTS TREATED 
WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR 
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OBJECTIVES: To compare value sets derived from EQ-5D US tariffs and VAS and 
TTO in individuals with chronic pDPN/PHN. METHODS: This analysis was con-
ducted using baseline responses from 3 longitudinal surveys of adults with ≥3 months 
of pDPN/PHN who were receiving pain medications. Of them, 2719 completed the 
EQ-5D and VAS and, 2109 completed TTOs. Three value-sets were derived using: 
the EQ-5D classiﬁer (US-value-set), VAS, and TTO, which elicits patient willingness-
to-trade time for reduced pain. Generalized linear models were used to compare the 
covariate-adjusted values, adjusting for age, income, overall pain quality, and pain 
severity (PS) using numerical rating scale ranging from 0 (“no pain”) to 10 (“pain as 
bad as you can imagine”). Derived values were compared along PS, across all respon-
dents and by subgroups according to degrees of social/psychological difﬁculties due 
to pain. RESULTS: Mean respondent age was 55.48 (±10.65) years and 58.73% 
reported having a PS ≥ 6. Due to pain, 84% reported feeling older, 60.30% reported 
not feeling like going out and 60.29% wanted to be left alone. Mean values for 
EQ-5D, VAS and TTO were 0.594 (±0.215), 0.482 (±0.231) and −6.010 (±17.573), 
respectively. Mean covariate-adjusted values were 0.586 (±0.128), 0.471 (±0.075) and 
−6.156 (±4.151), respectively. All values decreased monotonically as PS increased. This 
monotonic relationship was strongest for TTO (resulting in a value of −11.98 at PS 
= 10 after covariate adjustment), followed by the EQ-5D, and VAS (p < 0.001). Similar 
results were found in stratiﬁed groups, especially in those with greater pDPN/PHN-
related social/psychological difﬁculties compared to other patients (p < 0.05). CON-
CLUSIONS: All three value-sets show scores signiﬁcantly related to PS. Findings 
suggest that value-sets with lower-end constrains (VAS, EQ-5D) are likely to under-
estimate the true value of preventing pain and may not lead to correct prioritization 
when considering health states that involve moderate to severe pain.
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OBJECTIVES: The objective of this research was to identify domains of family social 
functioning that could be adversely impacted by SLE. METHODS: Twenty patients 
with SLE were interviewed on the impact of SLE in family functioning by telephone. 
Data were transcribed and descriptive statistics calculated. Domains were extracted 
using qualitative analysis evaluating relative support for the importance of each 
proposed domain. RESULTS: Participants were 18 females and 2 males (mean age = 
38). Most reported moderate to marked work disability, high-moderate social life 
disability and moderate disruption in family and home life. The meaning of “family” 
varied with 95% of patients listing immediate family members as their family, but 
70% included extended family. Six domains were identiﬁed: 1) Fatigue: When asked 
about the most bothersome symptom of SLE, fatigue was most frequently mentioned 
and reported as problematic by 90%; 2) Activities: 55% reported that ﬂares were 
unpredictable, but in contrast to what we anticipated, most patients learned how to 
cope with ﬂares. “active” activities (especially outdoor activities) were reportedly 
greatly affected by SLE; 3) Mental health: 88% reported that poor mental health 
impaired their ability to do the things that they liked to do with their families,;4) Isola-
tion: Withdrawal tended to occur during disease ﬂares. Such times were also often 
complicated by poor mood and extreme fatigue which contributed to the desire to be 
alone; 5) Of the 19 sexually active participants, 84% reported that SLE had a negative 
impact on their ability to have a gratifying sex life. Close to half reported that this 
distanced them from signiﬁcant others; and 6) Role Functioning: 80% described ways 
in which family roles were impacted, while 10% volunteered that SLE had signiﬁcantly 
impacted the family ﬁnancially. CONCLUSIONS: We found good support for 6 
domains related to family functioning in SLE and a questionnaire is being 
developed.
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WHAT ARE THE KEY ATTRIBUTES AND ENDPOINTS OF OVERWEIGHT 
AND OBESITY THERAPY? A CONCEPTUAL MAP OF PATIENT-CENTRED 
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OBJECTIVES: Overweight and obesity impose a great burden on society. Though 
advances in obesity therapy can be observed, the long-lasting outcome is dissatisfying. 
This study aims at the identiﬁcation of patient-relevant attributes and endpoints in 
overweight and obesity therapy. Qualitative and quantitative methods were applied 
to identify a conceptual map of key attributes and endpoints. METHODS: Literature 
review (PubMed/Medline), focus groups (N = 44) and expert interviews (N = 5) were 
conducted to elicit patient preference over attributes and endpoints. A questionnaire 
with 124 possible attributes was conducted with N = 201 patients. Finally psycho-
